[144] PTC Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

PTC Therapeutics (PTCT) reported a proposed sale under Rule 144 of 1,667 shares of its common stock, with an aggregate market value of $83,601.72. The shares represent restricted stock that vested and were acquired on 06/17/2025 as compensation.

The filing names Fidelity Brokerage Services LLC as the broker and lists an approximate sale date of 08/28/2025 on the NASDAQ. The company’s total shares outstanding are reported as 79,438,094, making the proposed sale a very small fraction of outstanding stock.

Positive

• Full disclosure of transaction details including acquisition date, nature (restricted stock vesting), broker, and approximate sale date
• Transaction size explicitly stated: 1,667 shares with aggregate value of $83,601.72

Negative

• None.

Insights

Securities/Equity Analyst

TL;DR: Routine insider sale of vested compensation shares; size is immaterial to market capitalization and unlikely to affect stock price.

The filing discloses a proposed Rule 144 sale of 1,667 common shares received from restricted stock vesting on 06/17/2025. The aggregate market value is $83,601.72 and the shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ around 08/28/2025. Relative to the reported 79,438,094 shares outstanding, the transaction represents a negligible percentage of the float, indicating limited direct impact on liquidity or valuation. No recent sales by the holder in the past three months are reported.

Compliance/Risk Analyst

TL;DR: Filing appears compliant with Rule 144 disclosure requirements; signer attests no undisclosed material adverse information.

The notice identifies the nature of acquisition as restricted stock vesting and states payment was compensation. The form includes the standard attestation that the seller is not aware of undisclosed material adverse information. No entries indicate aggregated prior sales in the past three months. Broker information and an approximate sale date are provided, aligning with typical Rule 144 procedural disclosures.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1667	83601.72	79438094	08/28/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/17/2025	Restricted Stock Vesting	Issuer			1667	06/17/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many PTCT shares are proposed for sale in this Form 144?

The filing proposes the sale of 1,667 common shares.

What is the aggregate market value of the shares to be sold for PTCT?

The aggregate market value reported is $83,601.72.

When were the shares acquired that are being sold under Rule 144?

The shares were acquired on 06/17/2025 upon restricted stock vesting.

Which broker is handling the proposed sale of PTCT shares?

The broker listed is Fidelity Brokerage Services LLC (900 Salem Street, Smithfield, RI).

What is the approximate date of the proposed sale?

The filing lists an approximate sale date of 08/28/2025 on NASDAQ.

How large is the proposed sale relative to PTCT's outstanding shares?

The company reports 79,438,094 shares outstanding; 1,667 shares are a very small percentage of that total.